The stroke treatment community has witnessed a historic milestone with the FDA Approval of TNKase (tenecteplase), Roche's groundbreaking therapy that represents the first new medication for acute ischemic stroke in nearly 30 years. This approval signals a significant shift in treatment options for a condition that strikes approximately 800,000 Americans annually and remains a leading...